Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

SNY US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Sanofi American Depositary Receipt(SNY US)

$48.40-0.060.12%(Market Open · 18:43:35 UTC)
Ask AI
Doc SearchProfileEntity StructureEDINET FilingsFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

SNY US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Sanofi American Depositary Receipt(SNY US)

$48.40-0.060.12%(Market Open · 18:43:35 UTC)
Ask AI
Doc SearchProfileEntity StructureEDINET FilingsFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings
EDINET Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees
EDINET Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Sanofi American Depositary Receipt — Company Profile

Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UQ
CEO
Belén Garijo López
Headquarters
Paris, I0, FR
IPO Date
Jul 1, 2002
Employees
76,493
Website
www.sanofi.com

Key Metrics

Price
$39.92
Market Cap
$95.86B
Revenue (TTM)
$11.24B
Net Income (TTM)
$1.61B
EPS (TTM)
0.67
P/E (TTM)
12.69
P/B (TTM)
1.32
Dividend Yield
5.58%
ROE (TTM)
10.95%
ROA (TTM)
6.16%
Operating Margin
20.54%
Beta
0.28

Dividends

Last Dividend
$2.42
Last Yield
0.06%

Summary

Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.

Website
www.sanofi.com
Location
Paris, I0, FR
Phone33 1 53 77 40 00
Employees76,493
CEOBelén Garijo López
Sector
Health Care
Industry
Pharmaceuticals
IPO DateJul 1, 2002

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(1.5K)

Expand
  • 13F-HRQuarterly report (institutional investment manager holdings)5 Nov
  • 6-KCurrent report (foreign private issuer)30 Oct
  • SC 13G/ASanofi26 Oct
  • 6-KCurrent report (foreign private issuer)26 Oct
  • 6-KCurrent report (foreign private issuer)1 Oct
  • 6-KCurrent report (foreign private issuer)17 Sep
  • N-PXAnnual report of proxy voting record25 Aug
  • Form 4Sanofi12 Aug
  • Form 3Sanofi12 Aug
  • Form 4Sanofi7 Aug
  • 6-KCurrent report (foreign private issuer)6 Aug
  • Form 3Sanofi4 Aug
  • 6-KCurrent report (foreign private issuer)30 Jul
  • 6-KCurrent report (foreign private issuer)30 Jul
  • 13F-HRQuarterly report (institutional investment manager holdings)28 Jul
  • 6-KCurrent report (foreign private issuer)27 Jul
  • SC 13G/ASanofi22 Jul
  • 6-KCurrent report (foreign private issuer)17 Jul
  • 6-KCurrent report (foreign private issuer)7 Jul
  • 11-KAnnual report (employee stock purchase/savings/profit sharing plans)30 Jun

EDINET Filings(28)

Expand
  • IRSemi-Annual Report (2026.01.01-2026.12.31)24 Sep
  • IRCorrection Extraordinary Report5 Jun
  • PRSAmended Securities Registration Statement5 Jun
  • PRSSecurities registration statement25 May
  • IRExtraordinary Report25 May
  • IRExtraordinary Report12 May
  • 10-KAnnual Securities Report (2025.01.01-2025.12.31)27 Apr
  • IRExtraordinary Report15 Apr
  • IRSemi-Annual Report (2025.01.01-2025.12.31)29 Sep 2025
  • PRSAmended Securities Registration Statement5 Jun 2025
  • IRCorrection Extraordinary Report5 Jun 2025
  • PRSSecurities registration statement30 May 2025
  • IRExtraordinary Report30 May 2025
  • 10-KAnnual Securities Report (2024.01.01-2024.12.31)27 Apr 2025
  • IRSemi-Annual Report (2024.01.01-2024.12.31)24 Sep 2024
  • PRSAmended Securities Registration Statement31 May 2024
  • IRCorrection Extraordinary Report31 May 2024
  • PRSSecurities registration statement22 May 2024
  • IRExtraordinary Report22 May 2024
  • 10-KAmended Annual Securities Report6 May 2024

News

  • 5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (November 2026)7 Nov
  • Nurix Therapeutics Announces Sanofi's Decision to Discontinue Development of STAT6 Degrader SAR4482723 Nov
  • Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues3 Nov
  • Sanofi Q3 Earnings Call Highlights30 Oct
  • Dupixent Is Still Booming. Sanofi's CEO Is Already Planning for Life Without It30 Oct
  • Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up30 Oct
  • Sanofi Q3 Earnings & Sales Beat, 2026 View Up, Shares Rise30 Oct
  • Sanofi CEO Sets Sights on Deals to Drive Turnaround30 Oct
  • Regeneron's Billion-Dollar Catalyst Flying Under Wall Street's Radar Ahead of Oct. 30 Earnings26 Oct
  • Sanofi: An Alluring And Balanced Mix Of Yield And Growth26 Oct
  • Sanofi: Why The Market Seems To Be Overpricing Pipeline Risk20 Oct
  • ScionxBio Announces Collaboration to Develop Long-Acting xRNA Therapeutics20 Oct
  • Enable Injections Announces Approval in Japan for CirCLIQ® Injector based on enFuse® On-Body Delivery System19 Oct
  • Press Release: Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany19 Oct
  • Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration15 Oct
  • Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?14 Oct
  • EU Accepts Sanofi's Concessions to Settle Antitrust Probe Over Vaccine Marketing14 Oct
  • Head to Head Review: Sanofi (NASDAQ:SNY) vs. Scilex (NASDAQ:SCLX)11 Oct
  • 5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% Plus (October 2026)10 Oct
  • Press Release : Availability of the aide-mémoire for Q3 2026 results6 Oct

Mentions in Filings

  • … scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations, including in the antibody arts. For example, the United States Supreme Court in Amgen, Inc. v. <strong>Sanofi</strong>(“Amgen”) recently held that Amgen’s patent claims to a class of antibodies functionally defined by their ability to bind a particular antigen were invalid for lack of enablement where the patent specification provided 26 …
    Jade Biosciences, Inc.Sanofi American Depositary Receipt·10-Q - Quarterly report Q3·Q3 26·07:29AM
  • … which cases either narrow the scope of patent protection available in certain circumstances or weaken the rights of patent owners in certain situations. For example, the Supreme Court of the United States held in Amgen v. <strong>Sanofi</strong> (2023) that a functionally claimed genus was invalid for failing to comply with the enablement requirement of the Patent Act. In addition, the U.S. Court of Appeals for the Federal Circuit issued a decision, In re Cellect …
    SUTRO BIOPHARMA, INC.Sanofi American Depositary Receipt·10-Q - Quarterly report Q3·Q3 26·12 Nov
  • … ment of cancer. However, if approved, WTX-330 may face competition from other IL-12 cytokine programs in clinical and preclinical development for 270 --- TABLE OF CONTENTS oncology indications, including programs from <strong>Sanofi</strong> S.A. (Amunix), DEKA Biosciences, Inc., DragonFly Therapeutics, Inc., Juno Therapeutics, Inc. (Bristol-Myers Squibb Company), OncoSec Medical Incorporated, PDS Biotechnology, Philogen S.p.A., Sonnet BioTherapeutics, Inc., …
    Werewolf Therapeutics, Inc.Sanofi American Depositary Receipt·424B3 - Prospectus filing (Rule 424(b)(3))·Q4 26·12 Nov
  • … ssociated ASCVD risk. In preclinical studies, STX-1200 surrogates achieved greater than 95% Lp(a) reduction in NHPs. Corporate Highlights • Nasdaq listing: The Company’s common stock began trading on the Nasdaq Global Market on July 24, 2026, under the ticker symbol “SCTX.” Scribe upsized its initial public offering and priced at the high end of the range. The Company also completed a concurrent private placement to <strong>Sanofi</strong> at the IPO price. •
    Scribe Therapeutics, Inc.Sanofi American Depositary Receipt·EX-99.1 - 8-K - Results of Operations and Financial Condition·Q4 26·12 Nov
  • … disease areas include large companies with significant financial resources, such as AbbVie Inc., Astellas Pharma Inc., Eli Lilly and Company, Johnson & Johnson, Merck & Company Inc., Regeneron Pharmaceuticals Inc., Roche, <strong>Sanofi</strong> and Vertex Pharmaceuticals Incorporated, and biopharmaceutical companies such as Apellis Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., EyePoint Inc., Kodiak Sciences Inc., Krystal Biotech Inc., Ocular Therape …
    4D Molecular Therapeutics, Inc.Sanofi American Depositary Receipt·10-Q - Quarterly report Q3·Q3 26·12 Nov
  • … ly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. For example, in Amgen Inc. v. <strong>Sanofi</strong>, 598 U.S. 594, the U.S. Supreme Court held that claims with functional language may face high hurdles in fulfilling the enablement requirement. In addition, in Juno Therapeutics, Inc. v. Kite Pharma, Inc. 10 F.4th 1330 (F …
    Electra Therapeutics, Inc.Sanofi American Depositary Receipt·10-Q - Quarterly report Q3·Q3 26·12 Nov

Key Stats

Trading

Px/Chg 1D$39.92 / -1.84%
Avg Volume3.41M
Beta0.28
Mkt Cap95.86B
FD Mkt Cap107.62B

Float

Shrs Out/Float2.40B / 2.17B
Short Float0.00%
Days to Cover1.22
Stock Repurchased$5.68B

Current Valuation

EV110.67B
EV/EBITDA8.77
EV/Sales2.34
P/B1.32
P/S2.02
FCF Yield1.66%
ROE10.95%
ROA6.16%
Current Ratio1.09

Dividend

Cash$2.42
Yield5.58%
Yield (TTM)5.58%

Estimates

P/E12.69
Est P/E0.00
Est EPS1.06
Est PEG0.00

Valuation

Metric5Yr AvgMar '23Mar '24Mar '25Apr '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-3.9416.1422.5325.13-142.9159.39
Price / Sales5.463.332.923.159.388.53
Price / Book Value1.631.811.641.801.601.32
Price / Free Cash Flow37.3216.2314.0823.7472.1360.40
ENTERPRISE VALUE METRICS
Enterprise Value132,921.6143,974.1131,965.2150,521.3127,479.5110,667.9
Enterprise Value / Sales6.083.553.173.4010.449.84
Enterprise Value / EBITDA22.0010.6611.5913.6433.3540.75
Enterprise Value / EBIT34.5213.8418.9620.2168.8750.74

Financials

Full Financials
Millions EUR5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue4.5%39,175.040,561.041,618.044,286.046,716.0
Gross Income5.8%26,920.028,679.028,990.031,081.033,667.0
EBITDA2%11,538.013,510.011,390.011,033.012,479.0
EBIT-4.5%8,187.010,402.06,961.07,447.06,801.0
Net Income5.9%6,223.08,371.05,400.05,560.07,813.0
EPS (Diluted)6.5%2.493.182.152.193.20
BALANCE SHEET
Cash & ST Inv-6.7%10,098.012,736.08,710.07,927.07,657.0
Total Assets1.3%120,242.0126,722.0126,464.0132,798.0126,806.0
Total Liabilities1.8%51,211.051,570.052,111.054,941.055,096.0
Total Shareholder Equity96.7%68,681.074,784.074,040.077,507.071,376.0
CASH FLOW
Net Operating Cash Flow3.6%10,522.010,526.010,258.09,081.012,132.2
Cap Ex-67.3%-2,043.0-2,201.0-1,619.0-3,195.0-1,988.6
Free Cash Flow4.6%8,479.08,325.08,639.05,886.010,143.7

Enterprise Value Bridge

Millions EUR13 Nov '26
Price (As of 13 Nov '26)48.43
Basic Shares2,401.20
Market Cap116,278.1
Diluted Shares2,400.00
Fully Diluted Shares Outstanding2,400.00
Fully Diluted Market Cap116,220.0
+Consolidated Debt19,845.0
−In-the-Money Convertible Debt—
+Capital Leases1,903.0
+Operating Leases—
−Cash & Equivalents-5,966.0
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest362.0
+Pension Liabilities—
Enterprise Value130,519.1

Segment data

Revenue

by Geography

  • Reportable Geographical Zones76%
  • Europe16%
  • China5%
  • France3%

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US

Sanofi American Depositary Receipt — Company Profile

Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UQ
CEO
Belén Garijo López
Headquarters
Paris, I0, FR
IPO Date
Jul 1, 2002
Employees
76,493
Website
www.sanofi.com

Key Metrics

Price
$39.92
Market Cap
$95.86B
Revenue (TTM)
$11.24B
Net Income (TTM)
$1.61B
EPS (TTM)
0.67
P/E (TTM)
12.69
P/B (TTM)
1.32
Dividend Yield
5.58%
ROE (TTM)
10.95%
ROA (TTM)
6.16%
Operating Margin
20.54%
Beta
0.28

Dividends

Last Dividend
$2.42
Last Yield
0.06%

Summary

Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.

Website
www.sanofi.com
Location
Paris, I0, FR
Phone33 1 53 77 40 00
Employees76,493
CEOBelén Garijo López
Sector
Health Care
Industry
Pharmaceuticals
IPO DateJul 1, 2002

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(1.5K)

Expand
  • 13F-HRQuarterly report (institutional investment manager holdings)5 Nov
  • 6-KCurrent report (foreign private issuer)30 Oct
  • SC 13G/ASanofi26 Oct
  • 6-KCurrent report (foreign private issuer)26 Oct
  • 6-KCurrent report (foreign private issuer)1 Oct
  • 6-KCurrent report (foreign private issuer)17 Sep
  • N-PXAnnual report of proxy voting record25 Aug
  • Form 4Sanofi12 Aug
  • Form 3Sanofi12 Aug
  • Form 4Sanofi7 Aug
  • 6-KCurrent report (foreign private issuer)6 Aug
  • Form 3Sanofi4 Aug
  • 6-KCurrent report (foreign private issuer)30 Jul
  • 6-KCurrent report (foreign private issuer)30 Jul
  • 13F-HRQuarterly report (institutional investment manager holdings)28 Jul
  • 6-KCurrent report (foreign private issuer)27 Jul
  • SC 13G/ASanofi22 Jul
  • 6-KCurrent report (foreign private issuer)17 Jul
  • 6-KCurrent report (foreign private issuer)7 Jul
  • 11-KAnnual report (employee stock purchase/savings/profit sharing plans)30 Jun

EDINET Filings(28)

Expand
  • IRSemi-Annual Report (2026.01.01-2026.12.31)24 Sep
  • IRCorrection Extraordinary Report5 Jun
  • PRSAmended Securities Registration Statement5 Jun
  • PRSSecurities registration statement25 May
  • IRExtraordinary Report25 May
  • IRExtraordinary Report12 May
  • 10-KAnnual Securities Report (2025.01.01-2025.12.31)27 Apr
  • IRExtraordinary Report15 Apr
  • IRSemi-Annual Report (2025.01.01-2025.12.31)29 Sep 2025
  • PRSAmended Securities Registration Statement5 Jun 2025
  • IRCorrection Extraordinary Report5 Jun 2025
  • PRSSecurities registration statement30 May 2025
  • IRExtraordinary Report30 May 2025
  • 10-KAnnual Securities Report (2024.01.01-2024.12.31)27 Apr 2025
  • IRSemi-Annual Report (2024.01.01-2024.12.31)24 Sep 2024
  • PRSAmended Securities Registration Statement31 May 2024
  • IRCorrection Extraordinary Report31 May 2024
  • PRSSecurities registration statement22 May 2024
  • IRExtraordinary Report22 May 2024
  • 10-KAmended Annual Securities Report6 May 2024

News

  • 5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (November 2026)7 Nov
  • Nurix Therapeutics Announces Sanofi's Decision to Discontinue Development of STAT6 Degrader SAR4482723 Nov
  • Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues3 Nov
  • Sanofi Q3 Earnings Call Highlights30 Oct
  • Dupixent Is Still Booming. Sanofi's CEO Is Already Planning for Life Without It30 Oct
  • Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up30 Oct
  • Sanofi Q3 Earnings & Sales Beat, 2026 View Up, Shares Rise30 Oct
  • Sanofi CEO Sets Sights on Deals to Drive Turnaround30 Oct
  • Regeneron's Billion-Dollar Catalyst Flying Under Wall Street's Radar Ahead of Oct. 30 Earnings26 Oct
  • Sanofi: An Alluring And Balanced Mix Of Yield And Growth26 Oct
  • Sanofi: Why The Market Seems To Be Overpricing Pipeline Risk20 Oct
  • ScionxBio Announces Collaboration to Develop Long-Acting xRNA Therapeutics20 Oct
  • Enable Injections Announces Approval in Japan for CirCLIQ® Injector based on enFuse® On-Body Delivery System19 Oct
  • Press Release: Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany19 Oct
  • Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration15 Oct
  • Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?14 Oct
  • EU Accepts Sanofi's Concessions to Settle Antitrust Probe Over Vaccine Marketing14 Oct
  • Head to Head Review: Sanofi (NASDAQ:SNY) vs. Scilex (NASDAQ:SCLX)11 Oct
  • 5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% Plus (October 2026)10 Oct
  • Press Release : Availability of the aide-mémoire for Q3 2026 results6 Oct

Mentions in Filings

  • … scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations, including in the antibody arts. For example, the United States Supreme Court in Amgen, Inc. v. <strong>Sanofi</strong>(“Amgen”) recently held that Amgen’s patent claims to a class of antibodies functionally defined by their ability to bind a particular antigen were invalid for lack of enablement where the patent specification provided 26 …
    Jade Biosciences, Inc.Sanofi American Depositary Receipt·10-Q - Quarterly report Q3·Q3 26·07:29AM
  • … which cases either narrow the scope of patent protection available in certain circumstances or weaken the rights of patent owners in certain situations. For example, the Supreme Court of the United States held in Amgen v. <strong>Sanofi</strong> (2023) that a functionally claimed genus was invalid for failing to comply with the enablement requirement of the Patent Act. In addition, the U.S. Court of Appeals for the Federal Circuit issued a decision, In re Cellect …
    SUTRO BIOPHARMA, INC.Sanofi American Depositary Receipt·10-Q - Quarterly report Q3·Q3 26·12 Nov
  • … ment of cancer. However, if approved, WTX-330 may face competition from other IL-12 cytokine programs in clinical and preclinical development for 270 --- TABLE OF CONTENTS oncology indications, including programs from <strong>Sanofi</strong> S.A. (Amunix), DEKA Biosciences, Inc., DragonFly Therapeutics, Inc., Juno Therapeutics, Inc. (Bristol-Myers Squibb Company), OncoSec Medical Incorporated, PDS Biotechnology, Philogen S.p.A., Sonnet BioTherapeutics, Inc., …
    Werewolf Therapeutics, Inc.Sanofi American Depositary Receipt·424B3 - Prospectus filing (Rule 424(b)(3))·Q4 26·12 Nov
  • … ssociated ASCVD risk. In preclinical studies, STX-1200 surrogates achieved greater than 95% Lp(a) reduction in NHPs. Corporate Highlights • Nasdaq listing: The Company’s common stock began trading on the Nasdaq Global Market on July 24, 2026, under the ticker symbol “SCTX.” Scribe upsized its initial public offering and priced at the high end of the range. The Company also completed a concurrent private placement to <strong>Sanofi</strong> at the IPO price. •
    Scribe Therapeutics, Inc.Sanofi American Depositary Receipt·EX-99.1 - 8-K - Results of Operations and Financial Condition·Q4 26·12 Nov
  • … disease areas include large companies with significant financial resources, such as AbbVie Inc., Astellas Pharma Inc., Eli Lilly and Company, Johnson & Johnson, Merck & Company Inc., Regeneron Pharmaceuticals Inc., Roche, <strong>Sanofi</strong> and Vertex Pharmaceuticals Incorporated, and biopharmaceutical companies such as Apellis Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., EyePoint Inc., Kodiak Sciences Inc., Krystal Biotech Inc., Ocular Therape …
    4D Molecular Therapeutics, Inc.Sanofi American Depositary Receipt·10-Q - Quarterly report Q3·Q3 26·12 Nov
  • … ly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. For example, in Amgen Inc. v. <strong>Sanofi</strong>, 598 U.S. 594, the U.S. Supreme Court held that claims with functional language may face high hurdles in fulfilling the enablement requirement. In addition, in Juno Therapeutics, Inc. v. Kite Pharma, Inc. 10 F.4th 1330 (F …
    Electra Therapeutics, Inc.Sanofi American Depositary Receipt·10-Q - Quarterly report Q3·Q3 26·12 Nov

Key Stats

Trading

Px/Chg 1D$39.92 / -1.84%
Avg Volume3.41M
Beta0.28
Mkt Cap95.86B
FD Mkt Cap107.62B

Float

Shrs Out/Float2.40B / 2.17B
Short Float0.00%
Days to Cover1.22
Stock Repurchased$5.68B

Current Valuation

EV110.67B
EV/EBITDA8.77
EV/Sales2.34
P/B1.32
P/S2.02
FCF Yield1.66%
ROE10.95%
ROA6.16%
Current Ratio1.09

Dividend

Cash$2.42
Yield5.58%
Yield (TTM)5.58%

Estimates

P/E12.69
Est P/E0.00
Est EPS1.06
Est PEG0.00

Valuation

Metric5Yr AvgMar '23Mar '24Mar '25Apr '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-3.9416.1422.5325.13-142.9159.39
Price / Sales5.463.332.923.159.388.53
Price / Book Value1.631.811.641.801.601.32
Price / Free Cash Flow37.3216.2314.0823.7472.1360.40
ENTERPRISE VALUE METRICS
Enterprise Value132,921.6143,974.1131,965.2150,521.3127,479.5110,667.9
Enterprise Value / Sales6.083.553.173.4010.449.84
Enterprise Value / EBITDA22.0010.6611.5913.6433.3540.75
Enterprise Value / EBIT34.5213.8418.9620.2168.8750.74

Financials

Full Financials
Millions EUR5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue4.5%39,175.040,561.041,618.044,286.046,716.0
Gross Income5.8%26,920.028,679.028,990.031,081.033,667.0
EBITDA2%11,538.013,510.011,390.011,033.012,479.0
EBIT-4.5%8,187.010,402.06,961.07,447.06,801.0
Net Income5.9%6,223.08,371.05,400.05,560.07,813.0
EPS (Diluted)6.5%2.493.182.152.193.20
BALANCE SHEET
Cash & ST Inv-6.7%10,098.012,736.08,710.07,927.07,657.0
Total Assets1.3%120,242.0126,722.0126,464.0132,798.0126,806.0
Total Liabilities1.8%51,211.051,570.052,111.054,941.055,096.0
Total Shareholder Equity96.7%68,681.074,784.074,040.077,507.071,376.0
CASH FLOW
Net Operating Cash Flow3.6%10,522.010,526.010,258.09,081.012,132.2
Cap Ex-67.3%-2,043.0-2,201.0-1,619.0-3,195.0-1,988.6
Free Cash Flow4.6%8,479.08,325.08,639.05,886.010,143.7

Enterprise Value Bridge

Millions EUR13 Nov '26
Price (As of 13 Nov '26)48.43
Basic Shares2,401.20
Market Cap116,278.1
Diluted Shares2,400.00
Fully Diluted Shares Outstanding2,400.00
Fully Diluted Market Cap116,220.0
+Consolidated Debt19,845.0
−In-the-Money Convertible Debt—
+Capital Leases1,903.0
+Operating Leases—
−Cash & Equivalents-5,966.0
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest362.0
+Pension Liabilities—
Enterprise Value130,519.1

Segment data

Revenue

by Geography

  • Reportable Geographical Zones76%
  • Europe16%
  • China5%
  • France3%

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US